Cargando…

Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance

Head and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive epithelial cancer with poor overall response rates to checkpoint inhibitor therapy (CPI) despite CPI being the recommended treatment for recurrent or metastatic HNSCC. Mechanisms of resistance to CPI in HNSCC are poorly understood. To id...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Maoxuan, Sade-Feldman, Moshe, Wirth, Lori, Lawrence, Michael S., Faden, Daniel L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548500/
https://www.ncbi.nlm.nih.gov/pubmed/36210388
http://dx.doi.org/10.1038/s41698-022-00314-3
_version_ 1784805445359108096
author Lin, Maoxuan
Sade-Feldman, Moshe
Wirth, Lori
Lawrence, Michael S.
Faden, Daniel L.
author_facet Lin, Maoxuan
Sade-Feldman, Moshe
Wirth, Lori
Lawrence, Michael S.
Faden, Daniel L.
author_sort Lin, Maoxuan
collection PubMed
description Head and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive epithelial cancer with poor overall response rates to checkpoint inhibitor therapy (CPI) despite CPI being the recommended treatment for recurrent or metastatic HNSCC. Mechanisms of resistance to CPI in HNSCC are poorly understood. To identify drivers of response and resistance to CPI in a unique patient who was believed to have developed three separate HNSCCs, we performed single-cell RNA-seq (scRNA-seq) profiling of two responding lesions and one progressive lesion that developed during CPI. Our results not only suggest interferon-induced APOBEC3-mediated acquired resistance as a mechanism of CPI resistance in the progressing lesion but further, that the lesion in question was actually a metastasis as opposed to a new primary tumor, highlighting the immense power of scRNA-seq as a clinical tool for inferring tumor origin and mechanisms of therapeutic resistance.
format Online
Article
Text
id pubmed-9548500
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95485002022-10-11 Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance Lin, Maoxuan Sade-Feldman, Moshe Wirth, Lori Lawrence, Michael S. Faden, Daniel L. NPJ Precis Oncol Case Report Head and Neck Squamous Cell Carcinoma (HNSCC) is an aggressive epithelial cancer with poor overall response rates to checkpoint inhibitor therapy (CPI) despite CPI being the recommended treatment for recurrent or metastatic HNSCC. Mechanisms of resistance to CPI in HNSCC are poorly understood. To identify drivers of response and resistance to CPI in a unique patient who was believed to have developed three separate HNSCCs, we performed single-cell RNA-seq (scRNA-seq) profiling of two responding lesions and one progressive lesion that developed during CPI. Our results not only suggest interferon-induced APOBEC3-mediated acquired resistance as a mechanism of CPI resistance in the progressing lesion but further, that the lesion in question was actually a metastasis as opposed to a new primary tumor, highlighting the immense power of scRNA-seq as a clinical tool for inferring tumor origin and mechanisms of therapeutic resistance. Nature Publishing Group UK 2022-10-10 /pmc/articles/PMC9548500/ /pubmed/36210388 http://dx.doi.org/10.1038/s41698-022-00314-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Lin, Maoxuan
Sade-Feldman, Moshe
Wirth, Lori
Lawrence, Michael S.
Faden, Daniel L.
Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title_full Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title_fullStr Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title_full_unstemmed Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title_short Single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
title_sort single-cell transcriptomic profiling for inferring tumor origin and mechanisms of therapeutic resistance
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548500/
https://www.ncbi.nlm.nih.gov/pubmed/36210388
http://dx.doi.org/10.1038/s41698-022-00314-3
work_keys_str_mv AT linmaoxuan singlecelltranscriptomicprofilingforinferringtumororiginandmechanismsoftherapeuticresistance
AT sadefeldmanmoshe singlecelltranscriptomicprofilingforinferringtumororiginandmechanismsoftherapeuticresistance
AT wirthlori singlecelltranscriptomicprofilingforinferringtumororiginandmechanismsoftherapeuticresistance
AT lawrencemichaels singlecelltranscriptomicprofilingforinferringtumororiginandmechanismsoftherapeuticresistance
AT fadendaniell singlecelltranscriptomicprofilingforinferringtumororiginandmechanismsoftherapeuticresistance